Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum (PfNDH2) is dispensable in the asexual blood stages

Hangjun Ke, Suresh M. Ganesan, Swati Dass, Joanne M. Morrisey, Sovitj Pou, Aaron Nilsen, Michael Riscoe, Michael W. Mather, Akhil B. Vaidya

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The battle against malaria has been substantially impeded by the recurrence of drug resistance in Plasmodium falciparum, the deadliest human malaria parasite. To counter the problem, novel antimalarial drugs are urgently needed, especially those that target unique pathways of the parasite, since they are less likely to have side effects. The mitochondrial type II NADH dehydrogenase (NDH2) of P. falciparum, PfNDH2 (PF3D7_0915000), has been considered a good prospective antimalarial drug target for over a decade, since malaria parasites lack the conventional multi-subunit NADH dehydrogenase, or Complex I, present in the mammalian mitochondrial electron transport chain (mtETC). Instead, Plasmodium parasites contain a single subunit NDH2, which lacks proton pumping activity and is absent in humans. A significant amount of effort has been expended to develop PfNDH2 specific inhibitors, yet the essentiality of PfNDH2 has not been convincingly verified. Herein, we knocked out PfNDH2 in P. falciparum via a CRISPR/Cas9 mediated approach. Deletion of PfNDH2 does not alter the parasite’s susceptibility to multiple mtETC inhibitors, including atovaquone and ELQ-300. We also show that the antimalarial activity of the fungal NDH2 inhibitor HDQ and its new derivative CK-2-68 is due to inhibition of the parasite cytochrome bc 1 complex rather than PfNDH2. These compounds directly inhibit the ubiquinol-cytochrome c reductase activity of the malarial bc 1 complex. Our results suggest that PfNDH2 is not likely a good antimalarial drug target.

Original languageEnglish (US)
Article numbere0214023
JournalPloS one
Volume14
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

NADH dehydrogenase
Plasmodium falciparum
Parasites
antimalarials
Blood
Antimalarials
parasites
blood
malaria
Malaria
electron transport chain
Electron Transport
ubiquinol-cytochrome-c reductase
Clustered Regularly Interspaced Short Palindromic Repeats
Atovaquone
NADH dehydrogenase (ubiquinone)
NADH Dehydrogenase
Plasmodium
Electron Transport Complex III
drug resistance

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum (PfNDH2) is dispensable in the asexual blood stages. / Ke, Hangjun; Ganesan, Suresh M.; Dass, Swati; Morrisey, Joanne M.; Pou, Sovitj; Nilsen, Aaron; Riscoe, Michael; Mather, Michael W.; Vaidya, Akhil B.

In: PloS one, Vol. 14, No. 4, e0214023, 01.04.2019.

Research output: Contribution to journalArticle

Ke, Hangjun ; Ganesan, Suresh M. ; Dass, Swati ; Morrisey, Joanne M. ; Pou, Sovitj ; Nilsen, Aaron ; Riscoe, Michael ; Mather, Michael W. ; Vaidya, Akhil B. / Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum (PfNDH2) is dispensable in the asexual blood stages. In: PloS one. 2019 ; Vol. 14, No. 4.
@article{8031d8a80a3d49b196ac17a19cf4cf3c,
title = "Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum (PfNDH2) is dispensable in the asexual blood stages",
abstract = "The battle against malaria has been substantially impeded by the recurrence of drug resistance in Plasmodium falciparum, the deadliest human malaria parasite. To counter the problem, novel antimalarial drugs are urgently needed, especially those that target unique pathways of the parasite, since they are less likely to have side effects. The mitochondrial type II NADH dehydrogenase (NDH2) of P. falciparum, PfNDH2 (PF3D7_0915000), has been considered a good prospective antimalarial drug target for over a decade, since malaria parasites lack the conventional multi-subunit NADH dehydrogenase, or Complex I, present in the mammalian mitochondrial electron transport chain (mtETC). Instead, Plasmodium parasites contain a single subunit NDH2, which lacks proton pumping activity and is absent in humans. A significant amount of effort has been expended to develop PfNDH2 specific inhibitors, yet the essentiality of PfNDH2 has not been convincingly verified. Herein, we knocked out PfNDH2 in P. falciparum via a CRISPR/Cas9 mediated approach. Deletion of PfNDH2 does not alter the parasite’s susceptibility to multiple mtETC inhibitors, including atovaquone and ELQ-300. We also show that the antimalarial activity of the fungal NDH2 inhibitor HDQ and its new derivative CK-2-68 is due to inhibition of the parasite cytochrome bc 1 complex rather than PfNDH2. These compounds directly inhibit the ubiquinol-cytochrome c reductase activity of the malarial bc 1 complex. Our results suggest that PfNDH2 is not likely a good antimalarial drug target.",
author = "Hangjun Ke and Ganesan, {Suresh M.} and Swati Dass and Morrisey, {Joanne M.} and Sovitj Pou and Aaron Nilsen and Michael Riscoe and Mather, {Michael W.} and Vaidya, {Akhil B.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1371/journal.pone.0214023",
language = "English (US)",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum (PfNDH2) is dispensable in the asexual blood stages

AU - Ke, Hangjun

AU - Ganesan, Suresh M.

AU - Dass, Swati

AU - Morrisey, Joanne M.

AU - Pou, Sovitj

AU - Nilsen, Aaron

AU - Riscoe, Michael

AU - Mather, Michael W.

AU - Vaidya, Akhil B.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - The battle against malaria has been substantially impeded by the recurrence of drug resistance in Plasmodium falciparum, the deadliest human malaria parasite. To counter the problem, novel antimalarial drugs are urgently needed, especially those that target unique pathways of the parasite, since they are less likely to have side effects. The mitochondrial type II NADH dehydrogenase (NDH2) of P. falciparum, PfNDH2 (PF3D7_0915000), has been considered a good prospective antimalarial drug target for over a decade, since malaria parasites lack the conventional multi-subunit NADH dehydrogenase, or Complex I, present in the mammalian mitochondrial electron transport chain (mtETC). Instead, Plasmodium parasites contain a single subunit NDH2, which lacks proton pumping activity and is absent in humans. A significant amount of effort has been expended to develop PfNDH2 specific inhibitors, yet the essentiality of PfNDH2 has not been convincingly verified. Herein, we knocked out PfNDH2 in P. falciparum via a CRISPR/Cas9 mediated approach. Deletion of PfNDH2 does not alter the parasite’s susceptibility to multiple mtETC inhibitors, including atovaquone and ELQ-300. We also show that the antimalarial activity of the fungal NDH2 inhibitor HDQ and its new derivative CK-2-68 is due to inhibition of the parasite cytochrome bc 1 complex rather than PfNDH2. These compounds directly inhibit the ubiquinol-cytochrome c reductase activity of the malarial bc 1 complex. Our results suggest that PfNDH2 is not likely a good antimalarial drug target.

AB - The battle against malaria has been substantially impeded by the recurrence of drug resistance in Plasmodium falciparum, the deadliest human malaria parasite. To counter the problem, novel antimalarial drugs are urgently needed, especially those that target unique pathways of the parasite, since they are less likely to have side effects. The mitochondrial type II NADH dehydrogenase (NDH2) of P. falciparum, PfNDH2 (PF3D7_0915000), has been considered a good prospective antimalarial drug target for over a decade, since malaria parasites lack the conventional multi-subunit NADH dehydrogenase, or Complex I, present in the mammalian mitochondrial electron transport chain (mtETC). Instead, Plasmodium parasites contain a single subunit NDH2, which lacks proton pumping activity and is absent in humans. A significant amount of effort has been expended to develop PfNDH2 specific inhibitors, yet the essentiality of PfNDH2 has not been convincingly verified. Herein, we knocked out PfNDH2 in P. falciparum via a CRISPR/Cas9 mediated approach. Deletion of PfNDH2 does not alter the parasite’s susceptibility to multiple mtETC inhibitors, including atovaquone and ELQ-300. We also show that the antimalarial activity of the fungal NDH2 inhibitor HDQ and its new derivative CK-2-68 is due to inhibition of the parasite cytochrome bc 1 complex rather than PfNDH2. These compounds directly inhibit the ubiquinol-cytochrome c reductase activity of the malarial bc 1 complex. Our results suggest that PfNDH2 is not likely a good antimalarial drug target.

UR - http://www.scopus.com/inward/record.url?scp=85064078091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064078091&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0214023

DO - 10.1371/journal.pone.0214023

M3 - Article

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0214023

ER -